Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
نویسندگان
چکیده
[This corrects the article DOI: 10.1371/journal.pone.0155406.].
منابع مشابه
The Antiretroviral Pregnancy Registry Interim Report.
ABACAVIR+LAMIVUDINE+ZIDOVUDINE (TRIZIVIR, TZV) ABACAVIR+DOLUTEGRAVIR+LAMIVUDINE (TRIUMEQ, TRI) ADEFOVIR DIPIVOXIL (HEPSERA, ADV) AMPRENAVIR (AGENERASE, APV) (AGENERASE NO LONGER MANUFACTURED AS OF 2007) ATAZANAVIR (REYATAZ, ATV) ATAZANAVIR+COBICISTAT (EVOTAZ, EVO) COBICISTAT (TYBOST, COBI) DARUNAVIR (PREZISTA, DRV) DARUNAVIR+COBICISTAT (PREZCOBIXTM, REZOLSTATM, PCX) DELAVIRDINE MESYLATE (RESCRI...
متن کاملAn Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
OBJECTIVES The objective of this analysis is to perform an indirect comparison of elvitegravir, cobicistat, emtricitabine and tenofovir DF (E/C/F/TDF) to abacavir/lamivudine and dolutegravir (ABC/3TC + DTG) by using 2 trials evaluating each of these regimens in comparison to efavirenz, emtricitabine and tenofovir DF (EFV/FTC/TDF). METHODS An indirect comparison was performed by using a genera...
متن کاملAn indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
BACKGROUND Integrase strand transfer inhibitors (INSTI) are the standard of care for naïve HIV-infected individuals due to their favourable efficacy and safety profile. The newest INSTIs, elvitegravir and dolutegravir, have not been evaluated in a head to head study; however, both have been compared to efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) in phase III trials. Elvitegravir/cobicistat/...
متن کامل48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis
BACKGROUND A network meta-analysis can provide estimates of relative efficacy for treatments not directly studied in head-to-head randomized controlled trials. We estimated the relative efficacy and safety of dolutegravir (DTG) versus third agents currently recommended by guidelines, including ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV), cobicistat...
متن کاملGreater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
OBJECTIVE Antiretroviral therapy initiation has been linked to bone mineral density and bone biomarker changes. We assessed long-term bone turnover biomarker effects over 144 weeks in patients initiating dolutegravir (DTG) + abacavir/lamivudine (ABC/3TC) versus efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF). METHODS Patients randomized in SINGLE received DTG (50 mg once d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 11 شماره
صفحات -
تاریخ انتشار 2016